Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In The News: Changes At Impax, Isarna, Sorrento, Macrogenics

Executive Summary

Actavis global R&D exec G. Frederick Wilkinson joins Impax as president and CEO; FDA veteran Shaw Chen moves to Polaris. On the government side, Senate HELP Cmte. Is slated to review Sylvia Burwell’s nomination for HHS secretary and Michael Hash is retiring from the department. More personnel announcements in this month’s column.

You may also be interested in...



European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals

Increased optimism about economic growth in Europe has been followed by IPOs becoming more common among the region’s biotech companies; there’s a speculation frenzy about M&A; and with European parliamentary elections in May, further regulatory and legislative changes are likely later in the year.

Hash Will Be HHS Health Reform Office Director As Administration Regroups For New Congress

White House health reform operative Michael Hash will move to director of the HHS Office of Health Reform, succeeding Jeanne Lambrew.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS056097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel